Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of TD-1058 in Healthy Subjects and Subjects With IPF
NCT04589260Phase 1Terminated
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing TD-1058 with Placebo (2 arms). Primary endpoint: Adverse Events. Started Oct 2020; status: terminated.
02
Drugs
TD-1058
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04589260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04589260.